Web-based Genetic Research on Parkinson's Disease
Trial
N/A
Completed
Nov. 2, 2022
Prebiotics in the Parkinson's Disease Microbiome
Trial
N/A
Completed
Nov. 2, 2022
Guideline for Hometitration With Duodopa for Parkinson Patients
Trial
N/A
Completed
Nov. 1, 2022
GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment
Trial
N/A
Completed
Nov. 1, 2022
The Calgary Movement Disorders Advanced Care Pilot Program
Trial
N/A
Unknown
Oct. 30, 2022
Vestibular Stimulation in Parkinson's Disease
Trial
N/A
Completed
Oct. 30, 2022
Biomarkers of Synaptic Damage in Multiple Sclerosis
Trial
N/A
Recruiting
Oct. 27, 2022
Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia
Trial
N/A
Completed
Oct. 27, 2022
Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
Trial
Early Phase 1
Unknown
Oct. 27, 2022
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Trial
Phase 2
Active, not recruiting
Oct. 26, 2022
Deep Brain Stimulation (DBS) for Parkinson's Disease International Study
Trial
N/A
Completed
Oct. 19, 2022
The Effect and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Impairments in PD
Trial
N/A
Unknown
Oct. 17, 2022
Establishing Alpha-synuclein RT-QuIC Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder
Trial
N/A
Withdrawn
Oct. 17, 2022
DESENSITIZE-PD: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Support Dopaminergic Desensitization in PD
Trial
N/A
Unknown
Oct. 17, 2022
Measuring Parkinson's Disease Progression
Trial
Phase 1
Completed
Oct. 13, 2022
Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
Trial
Phase 2
Withdrawn
Oct. 13, 2022
PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables
Trial
N/A
Completed
Oct. 11, 2022
Parkinson's Research With Inclusion, Diversity and Equity
Trial
N/A
Unknown
Oct. 9, 2022
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
Trial
Phase 2
Completed
Oct. 9, 2022
Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)
Trial
Phase 2
Completed
Oct. 5, 2022